FLT3 D835delinsLK
Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene FLT3
Variant D835delinsLK
Impact List indel
Protein Effect unknown
Gene Variant Descriptions FLT3 D835delinsLK results in the deletion of aspartic acid (D) at amino acid 835 in the protein kinase domain of the Flt3 protein, combined with the insertion of a leucine (L) and a lysine (K) at the same site (UniProt.org). D835delinsLK has been identified in the scientific literature (PMID: 40196870), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Sep 2025).
Associated Drug Resistance
Category Variants Paths

FLT3 mutant FLT3 exon20 FLT3 D835delinsLK

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_004119.3
gDNA chr13:g.28018503_28018505delinsCTTAAG
cDNA c.2503_2505delinsCTTAAG
Protein p.D835delinsLK
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_004119.3 chr13:g.28018503_28018505delinsCTTAAG c.2503_2505delinsCTTAAG p.D835delinsLK RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 D835delinsLK hematologic cancer sensitive Gilteritinib Preclinical Actionable In a preclinical study, Xospata (gilteritinib) treatment inhibited Flt3 signaling and viability in a cell line expressing FLT3 D835delinsLK in culture and inhibited growth in a transplant model (PMID: 40196870). 40196870
FLT3 D835delinsLK hematologic cancer decreased response Quizartinib Preclinical Actionable In a preclinical study, cells expressing FLT3 D835delinsLK were less sensitive to Vanflyta (quizartinib) compared to cells expressing a FLT3-ITD in culture and in a transplant model (PMID: 40196870). 40196870
FLT3 D835delinsLK hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835delinsLK in culture (PMID: 40196870). 40196870